Calithera Biosciences, Inc. 4
4 · Calithera Biosciences, Inc. · Filed Oct 9, 2014
Insider Transaction Report
Form 4
Christoffersen Ralph E
Director10% Owner
Transactions
- Conversion
SERIES B PREFERRED STOCK
2014-10-07+419,181→ 0 total(indirect: See Footnote)→ COMMON STOCK (419,181 underlying) - Conversion
SERIES D PREFERRED STOCK
2014-10-07+634,195→ 0 total(indirect: See Footnote)→ COMMON STOCK (634,195 underlying) - Conversion
COMMON STOCK
2014-10-07+1,811,915→ 1,811,915 total(indirect: By Partnership) - Conversion
SERIES A PREFERRED STOCK
2014-10-07+10,999→ 0 total(indirect: See Footnote)→ COMMON STOCK (10,999 underlying) - Purchase
COMMON STOCK
2014-10-07$10.00/sh+350,000$3,500,000→ 2,161,915 total(indirect: By Partnership) - Conversion
SERIES C PREFERRED STOCK
2014-10-07+747,540→ 0 total(indirect: See Footnote)→ COMMON STOCK (747,540 underlying)
Footnotes (2)
- [F1]The Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately upon consummation of Issuer's initial public offering of Common Stock and had no expiration date.
- [F2]The securities are held by Morgenthaler Venture Partners IX, L.P. (MVP IX). The managing partner of MVP IX is Morgenthaler Management Partners IX, LLC (MMP IX). Ralph E. Christoffersen, a director of the Issuer is a Member of MMP IX. As such, the Reporting Person shares voting and investment power over the securities held by MMP IX. The Reporting Person disclaims beneficial ownership of the securities held by MMP IX except to the extent of his pecuniary interest therein.